|
< back to headlines
Data Announcements Remain on Schedule with Two Abstracts
Accepted for Presentation, and Large Clinical Data Release
in November 2008
BRIDGEWATER, NJ
(September 4, 2008) — Aegerion Pharmaceuticals, Inc., a
specialty pharmaceutical company focused on the treatment of
cardiovascular and metabolic disease, today announced the
appointment of Peter L. Garrambone, Jr. to the Company’s
board of directors.
Peter Garrambone’s career includes more than 50
pharmaceutical transactions executed during his 24-year
tenure at Pfizer, where he was a senior vice president of
Corporate Strategic Planning. At Pfizer, Mr. Garrambone
led the company’s corporate business development and
strategic planning efforts. Most recently, Mr. Garrambone
was senior vice president of Business Development for
Reliant Pharmaceuticals, which was sold to GlaxoSmithKline
for $1.65 billion in the fall of 2007.
“We are fortunate that Peter is joining the board of
directors. His extensive strategic and licensing
transaction expertise will be invaluable as the company
continues the pursuit of its strategic plan with the
availability of its important clinical data in November of
this year,” said David Scheer, Chairman and Co-Founder of
Aegerion.
In furtherance of its strategic plan, the Company announced
that it had secured additional funding from investors to
support ongoing and future clinical trials. The Company
will be presenting an abstract at both the American
Association for the Study of Liver Disease and American
Heart Association Meetings in the fourth quarter of 2008.
Aegerion anticipates receiving the results of three Phase
II trials on AEGR 733 before the end of 2008. These trials,
comprised of more than 460 patients, are designed to explore
the efficacy, safety and tolerability of AEGR 733,
Aegerion’s lead compound. A Phase III study of AEGR 733 in
the orphan population of homozygous familial
hypercholesterolemic patients is currently underway.
In addition, Aegerion announced the transition of Jerry
Wisler, Co-Founder, CEO and Director of Aegerion, who has
left the Company to pursue personal interests.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. is a privately held specialty
pharmaceutical company focused on the development and
commercialization of promising pharmaceuticals to treat
cardiovascular and metabolic disease. The Company’s primary
focus is on hyperlipidemia. Its most advanced products have
demonstrated significant LDL lowering activity in human
trials and are currently in Phase III and Phase II testing.
Contact:
Will Lewis, Co-Founder, Senior Vice President and Chief
Financial Officer, Aegerion
(t) 908-707-2100
(e)
wlewis@aegerion.com
Kate Childress, Vox Medica Healthcare
(t) 215-238-8500 x1107
(e)
kchildress@voxmedica.com
|
